Transcriptional regulation by DNA methylation

Cancer Treatment Reviews

Volumn 37, Issue SUPPL. 1, 2011, Pages

  Poetsch, Anna R ^a   Plass, Christoph ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; MICRORNA;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMATIN; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; LEUKEMOGENESIS; NONHUMAN; REVIEW; TRANSCRIPTION REGULATION;

CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA; TRANSCRIPTION, GENETIC;

EID: 79960893287     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.04.010     Document Type: Review

References (57)

1. " INTERNATIONAL-HUMAN-GENOME-SEQUENCING-CONSORTIUM" Finishing the euchromatic sequence of the human genome. Nature 2004;431(7011):931-45.
2. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004;306(5696):636-40.
3. Monteiro ANA, Coetzee GA, Freedman ML, et al. Principles for the post-GWAS functional characterisation of risk loci. Nature Precedings; 2010.
4. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
5. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935.
6. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705.
7. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010.
8. Bird A., Taggart M., Frommer M., Miller O.J., Macleod D. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 1985, 40(1):91-99.
9. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987, 196(2):261-282.
10. Sasai N., Defossez P.A. Many paths to one goal? The proteins that recognize methylated DNA in eukaryotes. Int J Dev Biol 2009, 53(2-3):323-334.
11. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem 1983, 52:93-124.
12. Clark S.J., Harrison J., Frommer M. CpNpG methylation in mammalian cells. Nat Genet 1995, 10(1):20-27.
13. Agirre X., Vizmanos J.L., Calasanz M.J., Garcia-Delgado M., Larrayoz M.J., Novo F.J. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 2003, 22(7):1070-1072.
14. Lister R., Pelizzola M., Dowen R.H., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462(7271):315-322.
15. Hermann A., Gowher H., Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004, 61(19-20):2571-2587.
16. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99(3):247-257.
17. Li E., Bestor T.H., Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69(6):915-926.
18. Koutelou E., Hirsch C.L., Dent S.Y. Multiple faces of the SAGA complex. Curr Opin Cell Biol 2010, 22(3):374-382.
19. Vermeulen M., Eberl H.C., Matarese F., et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 2010, 142(6):967-980.
20. Grant P.A., Duggan L., Cote J., et al. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev 1997, 11(13):1640-1650.
21. Zhang X.Y., Varthi M., Sykes S.M., et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008, 29(1):102-111.
22. Zhang Y., Rohde C., Tierling S., et al. DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet 2009, 5(3):e1000438.
23. Meissner A., Mikkelsen T.S., Gu H., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454(7205):766-770.
24. Zhang Y., Jurkowska R., Soeroes S., et al. Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res 2010, 38(13):4246-4253.
25. Jenkins Y., Markovtsov V., Lang W., et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 2005, 16(12):5621-5629.
26. Bartke T., Vermeulen M., Xhemalce B., Robson S.C., Mann M., Kouzarides T. Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell 2010, 143(3):470-484.
27. Gama-Sosa M.A., Slagel V.A., Trewyn R.W., et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983, 11(19):6883-6894.
28. Barreto G., Schafer A., Marhold J., et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007, 445(7128):671-675.
29. Popp C., Dean W., Feng S., et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 2010, 463(7284):1101-1105.
30. Bhutani N., Brady J.J., Damian M., Sacco A., Corbel S.Y., Blau H.M. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010, 463(7284):1042-1047.
31. Gaudet F., Hodgson J.G., Eden A., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300(5618):489-492.
32. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21(35):5427-5440.
33. Costello J.F., Fruhwald M.C., Smiraglia D.J., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet 2000, 24(2):132-138.
34. Rush L.J., Dai Z., Smiraglia D.J., et al. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 2001, 97(10):3226-3233.
35. Brena R.M., Morrison C., Liyanarachchi S., et al. Aberrant DNA Methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med 2007, 4(3):e108.
36. Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17(1):13-27.
37. Mrozek K., Heinonen K., de la Chapelle A., Bloomfield C.D. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997, 24(1):17-31.
38. Lugthart S, Figueroa ME, Bindels E, et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2010.
39. Birkenmeier E.H., Gwynn B., Howard S., et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989, 3(8):1146-1156.
40. Fukuchi Y., Ito M., Shibata F., Kitamura T., Nakajima H. Activation of CCAAT/enhancer-binding protein alpha or PU.1 in hematopoietic stem cells leads to their reduced self-renewal and proliferation. Stem cells 2008, 26(12):3172-3181.
41. Wouters B.J., Jorda M.A., Keeshan K., et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007, 110(10):3706-3714.
42. Keeshan K., He Y., Wouters B.J., et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 2006, 10(5):401-411.
43. Leroy H., Roumier C., Huyghe P., Biggio V., Fenaux P., Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005, 19(3):329-334.
44. Dufour A., Schneider F., Metzeler K.H., et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010, 28(4):570-577.
45. Pabst T., Eyholzer M., Fos J., Mueller B.U. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009, 100(8):1343-1346.
46. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113(13):3088-3091.
47. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1909-1918.
48. Hackanson B., Bennett K.L., Brena R.M., et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008, 68(9):3142-3151.
49. Agrawal S., Hofmann W.K., Tidow N., et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007, 109(9):3895-3905.
50. Chim C.S., Wong A.S., Kwong Y.L. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 2002, 119(4):988-990.
51. Bennett K.L., Hackanson B., Smith L.T., et al. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 2007, 67(10):4657-4664.
52. Tada Y., Brena R.M., Hackanson B., Morrison C., Otterson G.A., Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 2006, 98(6):396-406.
53. Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features. Leuk Res 2010.
54. Pabst T., Mueller B.U., Zhang P., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27(3):263-270.
55. Perrotti D., Cesi V., Trotta R., et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002, 30(1):48-58.
56. Eiring A.M., Harb J.G., Neviani P., et al. MiR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010, 140(5):652-665.
57. Radomska H.S., Basseres D.S., Zheng R., et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006, 203(2):371-381.